Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotensin, Xenical, Brevibloc Need Continued Pediatric AE Monitoring – Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Pediatric Advisory Committee recommends continued monitoring for an additional year of pediatric adverse events associated with Novartis' anti-hypertensive Lotensin

You may also be interested in...



Xenical Rx-To-OTC Switch Filing Slated For This Year

A 2005 filing for over-the-counter sale of the obesity agent would be one year earlier than previously expected. GlaxoSmithKline has conducted double-blind, placebo-controlled trials with an orlistat 60 mg dose and has received “good encouragement” from FDA, CEO Garnier says.

Xenical Rx-To-OTC Switch Filing Slated For This Year

A 2005 filing for over-the-counter sale of the obesity agent would be one year earlier than previously expected. GlaxoSmithKline has conducted double-blind, placebo-controlled trials with an orlistat 60 mg dose and has received “good encouragement” from FDA, CEO Garnier says.

Pediatric Adverse Event Reporting Could Improve With Claims Database Analysis

FDA’s Pediatric Advisory Committee says the easiest short-term remedy for improving the quality of the agency’s adverse event reporting system would be claims database analysis, although the best method would be population-based active surveillance.

Topics

UsernamePublicRestriction

Register

OM004078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel